New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
09:15 EDTDTV, T, DISH, CPB, ITMN, GOGO, ABT, CGENOn The Fly: Pre-market Movers
HIGHER: InterMune (ITMN), up 5.8% after reporting results from Phase 3 ASCEND study evaluating pirfenidone, shares upgraded to Outperform at Leerink... Gogo (GOGO), up 3.8% after upgraded at UBS... Abbott (ABT), up 1.4% after upgraded at Credit Suisse citing higher growth assumptions with the acquisition of CFR Pharmaceuticals... Compugen (CGEN), up 2.4% after quarterly losses not as steep as expected. LOWER: AT&T (T), down 2.7% after acquiring DirecTV (DTV) in a stock-and-cash transaction for $95 per share. DirecTV sahres are down 1.9% following the announcement, which shares of its nearest competitor DISH Network (DISH) are also down about 1.8%... Campbell Soup (CPB), down 5% after revenues miss expectations, saying its sees fiscal year profit at low end of prior view... Genworth (GNW), down 2.2% after downgraded at Morgan Stanley.
News For DTV;T;DISH;CPB;ITMN;GOGO;ABT;CGEN From The Last 14 Days
Check below for free stories on DTV;T;DISH;CPB;ITMN;GOGO;ABT;CGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 14, 2014
12:39 EDTCGENCompugen jumps after announcing newly discovered proteins
Compugen (CGEN) is rallying after the company announced earlier today that it has extended discovery capabilities to additional immunomodulatory proteins. WHAT'S NOTABLE: Compugen announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the companyís pipeline program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints. The newly discovered proteins have been added to the companyís pipeline program as potential targets for cancer immunotherapy. Dr. Cohen-Dayag, CEO of Compugen, noted "We are of course very proud that in less than four years, we have established a growing position in this field, including a substantial early-stage pipeline of therapeutic product candidates for both oncology and immunology, based largely on our B7/CD28-like protein candidate discoveries. With todayís announcement, we are further broadening our early-stage pipeline with additional immunomodulatory opportunities and again demonstrating the power and flexibility of our predictive discovery capabilities." PRICE ACTION: In afternoon trading, Compugen 's stock rallied 51c, or almost 6%, to $9.39.
12:21 EDTABTOn The Fly: Midday Wrap
Subscribe for More Information
11:17 EDTTDemand Media announces divestiture of Creativebug and CoveritLive
Subscribe for More Information
11:13 EDTABTAbbott CEO aims to boost medical device line, Reuters says
Subscribe for More Information
10:34 EDTTAT&T joint venture acquires Creativebug from Demand Media for $10M
Otter Media, a joint venture between AT&T (T) and The Chernin Group, has acquired Creativebug from Demand Media (DMD), the companies announced earlier. Creativebug offers do-it-yourself video workshops featuring instruction from artists and designers. Demand Media confirmed in a regulatory filing earlier that it completed the sale of substantially all of the assets relating to its Creativebug business for $10.0M in cash. AT&T and The Chernin Group announced the formation of the joint venture to acquire, invest in and launch over-the-top video services previously on April 22.
09:31 EDTTAT&T, EPIX reach carriage agreement
Subscribe for More Information
09:16 EDTABTOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
08:55 EDTABTMylan says does not anticipate regulatory hurdles prohibiting close of deal
08:49 EDTABTMylan says Abbott assets unlike other mature generic drug portfolios
Subscribe for More Information
08:36 EDTABTMylan accretive tax inversion deal makes sense, says UBS
Subscribe for More Information
08:32 EDTTSynchronoss acquires Voxmobili for $26M in cash
Synchronoss (SNCR) announced its acquisition of Voxmobili, a wholly owned subsidiary of OnMobile Global. Voxmobiliís customers include AT&T (T), Airtel, Everything Everywhere, France Telecom, Orange (ORAN), T-Mobile (TMUS), and Vodafone (VOD). In consideration for the acquisition, Synchronoss paid approximately $26M in cash to OnMobile Global.
08:27 EDTABTMylan sees Abbott transaction to be 'immediately and significantly accretive'
Subscribe for More Information
08:26 EDTABTMylan sees $10B in pro forma 2014 sales after closing Abbott deal
Subscribe for More Information
08:12 EDTABTMylan says Abbott deal 'first in series' of planned transactions
Subscribe for More Information
07:28 EDTABTMylan to host conference call
Subscribe for More Information
07:20 EDTABTAbbott to host conference call
Conference call to discuss agreement to sell developed markets branded generics pharmaceuticals business to Mylan will be held on July 14 at 9:30 am. Webcast Link
06:33 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
06:33 EDTABTMylan to acquire Abbott assets in all-stock transaction valued at about $5.3B
Subscribe for More Information
06:31 EDTABTAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
July 13, 2014
20:22 EDTABTMylan near buying Europe-based drug portfolio from Abbott, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use